Distribution of certain drug products by registered blood establishments and comprehensive hemophilia diagnostic treatment centers that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements and administrative procedures. Final rule.
The Food and Drug Administration (FDA) is amending its regulations to allow certain registered blood establishments and comprehensive hemophilia diagnostic treatment centers that are also health care entities to distribute certain drug products. The final rule amends limited provisions of the regulations implementing the Prescription Drug Marketing Act of 1987 (PDMA), as modified by the Prescription Drug Amendments of 1992 (PDA). These regulations, among other things, restrict the sale, purchase, or trade of, or the offer to sell, purchase, or trade, prescription drugs purchased by hospitals and other health care entities.
D000554:Ambulatory Care Facilities / Q000191:economics / Q000331:legislation & jurisprudence*; D001688:Biological Products / Q000191:economics; D001769:Blood; D011307:Drug Prescriptions; D006801:Humans; D007880:Legislation, Drug; D008389:Marketing of Health Services / Q000331:legislation & jurisprudence*; D004364:Pharmaceutical Preparations / Q000600:supply & distribution*; D014481:United States
D001688:Biological Products; D004364:Pharmaceutical Preparations